Sarepta expects Q3 net product revenue to reach $167M in Q3

Baris-Ozer/iStock via Getty Images

  • Announcing preliminary financial results for its third quarter that ended Sept. 30, Sarepta Therapeutics (NASDAQ:SRPT) says its net product revenues could reach approximately $166.9M indicating a ~37.5% growth from the…

Click here to view the original article.